

Key Information Document

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

You are about to purchase a product that is not simple and may be difficult to understand.

Product

| | |
|---|--|
| Product name | Autocallable Worst-of Reverse Convertible Certificate Linked to a Basket of Underlyings |
| Product identifier | ISIN: IT0006771932 |
| PRIIP manufacturer | Marex Financial (www.marexjp.com) Call +44 20 8050 3568 or +39 02 3056 9828 for more information. |
| Competent authority of the PRIIP manufacturer | Authorised and regulated by the U.K. Financial Conduct Authority |
| Date and time of production | 30 April 2026 7:13 Rome local time |

1. What is this product?

Type English law governed equity-linked certificates / Return depends on the performance of the underlyings / No capital protection against market risk

Term The product has a fixed term and will be due on 13 September 2029, subject to an early redemption.

Objectives The product is designed to provide a return in the form of (1) regular fixed coupon payments and (2) a cash payment on termination of the product. The timing and amount of this payment will depend on the performance of the **underlyings**. If, at maturity, the **final reference price** of the **worst performing underlying** has fallen below its **strike price**, the product may return less than the **product notional amount** or even zero.

(Terms that appear in **bold** in this section are described in more detail in the table(s) below.)

Early termination following an autocall: The product will terminate prior to the **maturity date** if, on any **autocall observation date**, the **reference price** of the **worst performing underlying** is above the relevant **autocall barrier price**. On any such early termination, you will on the immediately following **autocall payment date** receive, in addition to a final coupon payment, a cash payment equal to the autocall payment of EUR 1,000.00. No coupon payments will be made on any date after such **autocall payment date**.

Coupon: If the product has not terminated early, on each **coupon payment date** you will receive a coupon payment of EUR 6.80. The coupon payments are not linked to the performance of the **underlyings**.

Termination on the maturity date: If the product has not terminated early, on the **maturity date** you will receive:

- if the **final reference price** of the **worst performing underlying** is at or above its **strike price**, a cash payment equal to EUR 1,000.00; or
- if the **final reference price** of the **worst performing underlying** is below its **strike price**, a cash payment directly linked to the performance of the **worst performing underlying**. The cash payment will equal (i) the **product notional amount** multiplied by (ii) (A) the **final reference price** of the **worst performing underlying** divided by (B) its **strike price**.

Under the product terms, certain dates specified below will be adjusted if the respective date is either not a business day or not a trading day (as applicable). Any adjustments may affect the return, if any, you receive.

The product terms also provide that if certain exceptional events occur (1) adjustments may be made to the product and/or (2) the issuer may terminate the product early. These events are specified in the product terms and principally relate to the **underlyings**, the product and the issuer. The return (if any) you receive on such early termination is likely to be different from the scenarios described above and may be less than the amount you invested.

When purchasing this product during its lifetime, the purchase price may include accrued coupon on a pro rata basis.

You do not have any entitlement to a dividend from any of the **underlyings** and you have no right to any further entitlement resulting from any such **underlying** (e.g., voting rights).

| | | | |
|--------------------------------|--|-----------------------------------|---|
| Underlyings | Ordinary shares of Bayer AG (BAYN; ISIN: DE000BAY0017; Bloomberg: BAYN GY Equity), Bristol-Myers Squibb Co (BMY; ISIN: US1101221083; Bloomberg: BMY UN Equity) and Pfizer Inc (PFE; ISIN: US7170811035; Bloomberg: PFE UN Equity) and American Depositary Receipts of Novo Nordisk A/S (NVO; ISIN: US6701002056; Bloomberg: NVO UN Equity) | Final reference price | The reference price on the final valuation date |
| Underlying market | Equity | Initial valuation date | 1 December 2025 |
| Product notional amount | EUR 1,000.00 | Final valuation date | 4 September 2029 |
| Product currency | Euro (EUR) | Maturity date / term | 13 September 2029 |
| Underlying currencies | • BAYN: EUR • NVO: U.S. Dollar (USD) • BMY: USD • PFE: USD | Autocall observation dates | The 1st calendar day of each month from April 2026 (inclusive) to the final valuation date (inclusive) |
| Issue date | 27 November 2025 | Autocall barrier prices | On the first autocall observation date , the initial autocall barrier price ; thereafter decreasing by 1.00 |

(product ends after 3 years and 4 months) Average return each year

8.73%

7.43%

The favourable, moderate, unfavourable and stress scenarios represent possible outcomes that have been calculated based on simulations using the past performance of the **underlyings** over a period of up to 5 years. In the case of an early redemption, it has been assumed that no reinvestment has occurred. The stress scenario shows what you might get back in extreme market circumstances. This product cannot be easily cashed in. If you exit the investment earlier than the recommended holding period, you do not have a guarantee and you may have to pay extra costs.

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

3. What happens if Marex Financial is unable to pay out?

You are exposed to the risk that the issuer might be unable to meet its obligations in connection with the product for instance in the event of bankruptcy or an official directive for resolution action. This may materially adversely affect the value of the product and could lead to you losing some or all of your investment in the product. The product is not covered by any deposit protection scheme.

4. What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different investment periods.

The duration of this product is uncertain as it may terminate at different times depending on how the market evolves. The amounts shown here consider two different scenarios (early call and maturity). In case you decide to exit before the product ends, exit costs may apply in addition to the amounts shown here.

We have assumed:

- EUR 10,000 is invested
- a performance of the product that is consistent with each holding period shown.

| | <i>If the product is called at the first possible date, on 13 May 2026</i> | <i>If the product reaches maturity</i> |
|----------------------------|--|--|
| Total costs | EUR 105 | EUR 105 |
| Annual cost impact* | 1.13% | 0.32% each year |

*This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at maturity your average return per year is projected to be 3.04% before costs and 2.72% after costs.

We may share part of the costs with the person selling you the product to cover the services they provide to you. They will inform you of the amount.

Composition of costs

| | One-off costs upon entry or exit | If you exit after 1 year |
|--------------------|--|---------------------------------|
| Entry costs | 1.05% of the amount you pay when entering this investment. These costs are already included in the price you pay. | EUR 105 |
| Exit costs | 0.53% of your investment before it is paid out to you. These costs are already included in the price you receive and are only incurred if you exit before maturity. If an early redemption occurs or if you hold the product until maturity, no exit costs will be incurred. | EUR 53 |

5. How long should I hold it and can I take money out early?

Recommended holding period: 3 years and 4 months

The product aims to provide you with the return described under "1. What is this product?" above. However, this only applies if the product is held to maturity. It is therefore recommended that the product is held until 13 September 2029 (maturity), although the product may terminate early.

The product does not guarantee the possibility to disinvest other than by selling the product either (1) through the exchange (if the product is exchange traded) or (2) off-exchange, where an offer for such product exists. Save as otherwise disclosed in exit costs (see section "4. What are the costs?" above), no fees or penalties will be charged by the issuer for any such transaction, however an execution fee might be chargeable by your broker if applicable. By selling the product before its maturity, you may receive back less than you would have received if you had kept the product until maturity.

| | | | |
|-------------------------------|---------|------------------------|-------|
| Exchange listing | EuroTLX | Price quotation | Units |
| Smallest tradable unit | 1 unit | | |

In volatile or unusual market conditions, or in the event of technical faults/disruptions, the purchase and/or sale of the product can be temporarily hindered and/or suspended and may not be possible at all.

6. How can I complain?

Any complaint regarding the conduct of the person advising on, or selling, the product can be submitted directly to that person.

Any complaint regarding the product or the conduct of the manufacturer of this product can be submitted in writing at the following address: Marex Financial, 155 Bishopsgate, London, EC2M 3TQ, United Kingdom, by email to: complaints@marexfp.com or at the following website: www.marexfp.com.

7. Other relevant information

Any additional documentation in relation to the product, in particular, the issuance programme documentation, any supplements thereto and the product terms are published on www.certificati.marex.com, all in accordance with relevant legal requirements. These documents are also available free of charge from Marex Financial, 155 Bishopsgate, London, EC2M 3TQ, United Kingdom. Call +44 (0)208-050-8636 for more information.